The startup offers personalized wound care solutions utilizing advanced biomaterials and smart dressings that promote faster healing and reduce infection risk. Their technology addresses the challenges of chronic wounds by providing tailored treatment options that enhance patient outcomes and minimize healthcare costs.
Funding
$13.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic wounds pose significant challenges due to slow healing rates, high infection risks, and the need for frequent clinical interventions. Traditional wound care methods often fail to provide the personalized treatment required for complex wounds, leading to prolonged patient suffering and increased healthcare costs.
Solution
The startup develops advanced wound care solutions centered around biomaterials and smart dressings designed to accelerate healing and minimize infection. Their approach focuses on creating personalized treatment plans tailored to the specific characteristics of each wound, addressing the underlying factors that impede the healing process. By utilizing innovative materials and technologies, they aim to improve patient outcomes, reduce the frequency of dressing changes, and lower the overall cost of wound management.
Target Audience
The primary target audience includes hospitals, wound care clinics, long-term care facilities, and home healthcare providers specializing in the treatment of chronic wounds.
Features
- Advanced biomaterial matrices that promote cell proliferation and tissue regeneration
- Smart dressings with integrated sensors for real-time monitoring of wound parameters (e.g., pH, temperature, moisture levels)
- Data analytics platform that uses sensor data to optimize treatment protocols and predict healing progress
- Customizable dressing designs to accommodate various wound sizes, shapes, and locations
- Antimicrobial coatings to prevent infection and reduce the need for systemic antibiotics